Presentations on ROS1+ Cancer at IASLC #WCLC2018


Members of The ROS1ders will be attending The International Association for the Study of Lung Cancer’s (IASLC) annual World Conference on Lung Cancer (WCLC) in Toronto, Canada, September 23-26, 2018.  The Twitter hashtag for the conference is #WCLC2018. Presentations that will mention ROS1+ cancer are listed below.  The abstract book containing these and other WCLC … Continue reading Presentations on ROS1+ Cancer at IASLC #WCLC2018

Detection of ROS1 rearrangement in lung cancer remains “complex”


“No testing methodology demonstrated 100% sensitivity in the detection of ROS1 rearrangements or fusions among patients with non-small cell lung cancer, according to study results.” “The main point is just to be aware of the deficiencies in these assays and not to always trust a negative result from a single test,” Kurtis D. Davies, PhD, … Continue reading Detection of ROS1 rearrangement in lung cancer remains “complex”

IASLC Webinar 2018-02-06: Treatment Strategies for ROS1 Non-Small Cell Lung Cancer


This event is produced by the International Association for the Study of Lung Cancer (IASLC).  For more information and to register for the webinar, visit IASLC’s webinar registration page. If you are unable to participate in the webinar in real time, you can view the video on IASLC’s webinar page a few days after the webinar concludes.

Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC


An 2018 update to the lung cancer molecular testing guideline says testing for ROS1 rearrangements is strongly recommended for all lung cancer patients regardless of clinical characteristics. The article “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” was published online January 23, 2018, in the Journal of … Continue reading Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC